Hamburg, Germany-based biotech Evotec (FSE: EVT) has launched a partnership in diabetes with Canadian company Sernova (TSX-V: SVA), a regenerative medicines specialist.
Sernova is working on cell therapies, and will collaborate with Evotec to develop an implantable induced pluripotent stem cell (iPSC)-based treatment for insulin-dependent diabetes, including type 1 and 2.
The partnership will leverage iPSC-based beta cells from Evotec’s QRbeta initiative, which will be combined with Sernova’s proprietary Cell Pouch, an implantable medical device.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze